ORKA

Business Context and Reporting Period

Company: Hyseq, Inc. (Note: Input metadata referenced "Oruka Therapeutics," but the filing text identifies the registrant as Hyseq, Inc.)
Reporting Period: Fiscal year ended December 31, 2000.
Business Overview: Hyseq is a biopharmaceutical company engaged in the research and development of novel products using proprietary sequencing-by-hybridization (SBH) technology. The company has transitioned from pure gene discovery to advancing therapeutic protein candidates, specifically IL-1Hy1 (inflammatory diseases) and CD39L4 (heart disease), both currently in preclinical stages. Revenue is derived primarily from collaborative research agreements with partners such as BASF, Chiron, and Kirin.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: Contract revenues increased 144% to $15.6 million, driven primarily by the BASF collaboration ($11.7 million) which reached full contractual capacity in the second half of 2000.
• Expense Growth: Total operating expenses rose 46% to $38.3 million. R&D expenses increased by $10.8 million due to added scientific personnel, outside contract services, and supplies. G&A expenses increased by $1.2 million, largely due to new facility leases and legal fees related to patent litigation.
• Liquidity Deterioration: Cash and cash equivalents dropped from $30.6 million (including short-term investments) in 1999 to $2.7 million in 2000. Working capital turned negative to $(2.6) million, reflecting significant cash burn from operations ($21.0 million used) and capital expenditures ($8.3 million).
• Facility Expansion: The company leased an additional 59,000 square feet of space in Sunnyvale, CA, with lease payments averaging $317,000 per month, requiring significant upfront capital and future financing.

Guidance, Outlook, Risks, and Contingencies

• Financing Needs: Management explicitly states the need to secure additional financing before the end of fiscal 2001 to complete facility build-outs and fund R&D. A $20 million line of credit from the Chairman was drawn down in March 2001 and converted to equity.
• Product Outlook: No products are expected to generate revenue for several years. The company is advancing IL-1Hy1 and CD39L4 toward Investigational New Drug (IND) applications but faces significant regulatory and clinical risks.
• Legal Contingencies: Hyseq is engaged in complex, multi-suit patent litigation with Affymetrix, Inc. regarding SBH technology. Hyseq alleges infringement by Affymetrix, while Affymetrix countersues alleging invalidity and infringement of its own patents. Outcomes are uncertain and could materially impact the business.
• Collaboration Risks: Revenue is heavily dependent on a few partners (BASF accounted for 75% of 2000 revenue). Failure to maintain these relationships or meet performance milestones could severely impact liquidity.
• Profitability: The company has a history of operating losses and an accumulated deficit of $71.9 million. It does not expect to be profitable in the foreseeable future.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $2.7 million cash balance against the $42 million in future lease commitments and ongoing R&D burn rate.
• Financing Status: Confirm the status of the $20 million line of credit conversion and any subsequent equity or debt financing secured post-filing.
• Litigation Progress: Monitor the status of the Affymetrix patent litigation, as a loss could invalidate core technology rights.
• Collaboration Milestones: Review performance against the BASF agreement data generation requirements to ensure continued revenue recognition.
• Facility Build-out: Assess the timeline and cost of the new 59,000 sq. ft. facility expansion and its impact on cash flow.